AUTHOR=Mpanya Dineo , Sathekge Mike , Klug Eric , Damelin Jenna , More Stuart , Hadebe Bawinile , Vorster Mariza , Tsabedze Nqoba 

TITLE=Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease

JOURNAL=Frontiers in Nuclear Medicine

VOLUME=3

YEAR=2023

URL=https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2023.1224905

DOI=10.3389/fnume.2023.1224905

ISSN=2673-8880

ABSTRACT=<p>Gallium-68 fibroblast activation protein inhibitor [(<sup>68</sup>Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(<sup>18</sup>F)FDG] using positron emission tomography (PET). While imaging oncology patients with [<sup>68</sup>Ga]Ga-FAPI PET, incidental uptake of [<sup>68</sup>Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.</p>